Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-042000
Filing Date
2025-03-19
Accepted
2025-03-19 16:11:20
Documents
9

Document Format Files

Seq Description Document Type Size
1 DEFA14A 2025_nna_proxy_card.htm DEFA14A 98225
2 GRAPHIC img155345309_0.jpg GRAPHIC 6487
3 GRAPHIC img155345309_1.jpg GRAPHIC 18481
4 GRAPHIC img155345309_2.jpg GRAPHIC 2293
5 GRAPHIC img155345309_3.jpg GRAPHIC 9789
6 GRAPHIC img155345309_4.jpg GRAPHIC 1487
7 GRAPHIC img155345309_5.jpg GRAPHIC 1725
8 GRAPHIC img155345309_6.jpg GRAPHIC 1860
9 GRAPHIC img155345309_7.jpg GRAPHIC 2293
  Complete submission text file 0000950170-25-042000.txt   161651
Mailing Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121
Business Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121 8587318389
aTYR PHARMA INC (Filer) CIK: 0001339970 (see all company filings)

EIN.: 203435077 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37378 | Film No.: 25752806
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)